Fig. 2From: Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancySchematic representation of radiographic tumor burden over time indicating (left-to-right): baseline pre-everolimus scan, best response to everolimus, progression on everolimus and baseline pre-nivolumab scan, initial post-nivolumab response, and continued response at the time of nivolumab discontinuationBack to article page